CCL22 peptide vaccine

The CCL22 peptide vaccine is a preclinical-stage cancer immunotherapy developed by IO Biotech. It consists of peptides derived from the signal sequence of the chemokine CCL22 (C-C Motif Chemokine Ligand 22). The vaccine is designed to activate and expand CCL22-specific effector T cells, primarily CD8+ T cells, which then target and reduce CCL22-expressing cells in the tumor microenvironment (TME). CCL22 is a key chemokine involved in the recruitment of immunosuppressive regulatory T cells (Tregs) via the CCR4 axis. By reducing CCL22 levels, the vaccine aims to decrease Treg infiltration and promote a more pro-inflammatory TME, characterized by increased infiltration of CD8+ cytotoxic T cells and M1 macrophages. Preclinical studies in mouse models of colon carcinoma, melanoma, and pancreatic cancer have demonstrated that this approach can delay tumor growth and enhance survival.

Other names

CCL22-based vaccineCCL-22-based vaccineCCL 22-based vaccineCCL22-targeting peptide vaccineCCL-22-targeting peptide vaccineCCL 22-targeting peptide vaccine